Cargando…
Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant
Aprepitant, a selective high-affinity antagonist of human substance P/neurokinin 1 (NK(1)) receptors, is the active ingredient of EMEND(®) which has recently been approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant undergoes extensive metabolism, pri...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673828/ https://www.ncbi.nlm.nih.gov/pubmed/17722507 |